scaav9.u1a.hsgsh
Gene therapyexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02716246)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- N-sulphoglucosamine sulphohydrolaseSupplementation
supplementation - SGSH
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- scaav9.u1a.hsgsh
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04088734 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Abeona Therapeutics, University of Adelaide, University of Pittsburgh, University of Santiago de Compostela |
| NCT02716246 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2016 | Abeona Therapeutics, Ohio State University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abeona Therapeutics | For profit | 2 | 1 | 1 | 2016 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Adelaide | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Santiago de Compostela | Academic/Hospital | 1 | 0 | 1 | 2019 |
5 organizations
Page 1 / 1